Press release

Categories, unlike tags, can have a hierarchy.

Diffusion Pharmaceuticals Announces Strategic Review Process to Evaluate Value-Enhancing Alternatives including Opportunities to Better Leverage TSC

Diffusion Pharmaceuticals Announces Strategic Review Process to Evaluate Value-Enhancing Alternatives including Opportunities to Better Leverage TSC 150 150 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., Oct. 25, 2022 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc.

https://investors.diffusionpharma.com/News/news-details/2022/Diffusion-Pharmaceuticals-Announces-Strategic-Review-Process-to-Evaluate-Value-Enhancing-Alternatives-including-Opportunities-to-Better-Leverage-TSC/default.aspx

Diffusion Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

Diffusion Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update 150 150 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., Aug. 11, 2022 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc.

https://investors.diffusionpharma.com/News/news-details/2022/Diffusion-Pharmaceuticals-Reports-Second-Quarter-2022-Financial-Results-and-Provides-Business-Update/default.aspx

Diffusion Pharmaceuticals to Initiate Phase 2 Trial in Patients with Glioblastoma Multiforme Incorporating Innovative Imaging Methodology to Evaluate Tumor Oxygenation

Diffusion Pharmaceuticals to Initiate Phase 2 Trial in Patients with Glioblastoma Multiforme Incorporating Innovative Imaging Methodology to Evaluate Tumor Oxygenation 150 150 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., July 26, 2022 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc.

https://investors.diffusionpharma.com/News/news-details/2022/Diffusion-Pharmaceuticals-to-Initiate-Phase-2-Trial-in-Patients-with-Glioblastoma-Multiforme-Incorporating-Innovative-Imaging-Methodology-to-Evaluate-Tumor-Oxygenation/default.aspx

Diffusion Pharmaceuticals Announces Positive Effects in Altitude Trial

Diffusion Pharmaceuticals Announces Positive Effects in Altitude Trial 150 150 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., June 23, 2022 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc.

https://investors.diffusionpharma.com/News/news-details/2022/Diffusion-Pharmaceuticals-Announces-Positive-Effects-in-Altitude-Trial/default.aspx

Diffusion Pharmaceuticals Announces Appointment of Raven Jaeger, M.S., as Chief Regulatory Officer
Diffusion Pharmaceuticals Announces Appointment of Raven Jaeger, M.S., as Chief Regulatory Officer 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., May 18, 2022 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference
Diffusion Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., May 17, 2022 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
Diffusion Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., May 12, 2022 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Regains Compliance With Nasdaq Listing Requirements
Diffusion Pharmaceuticals Regains Compliance With Nasdaq Listing Requirements 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., May 04, 2022 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Announces 1-for-50 Reverse Stock Split as Part of Nasdaq Compliance Plan
Diffusion Pharmaceuticals Announces 1-for-50 Reverse Stock Split as Part of Nasdaq Compliance Plan 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., April 18, 2022 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Completes Dosing in Altitude Trial
Diffusion Pharmaceuticals Completes Dosing in Altitude Trial 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., April 11, 2022 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc.

Back to top